1. INTRODUCTION {#sec1}
===============

Immune Checkpoint Inhibitors (ICIs) are a new promising class of anti-tumor drugs that block negative costimulation of T-cells leading to an enhanced anti-tumor immune response. Targets of these therapies include cytotoxic T-lymphocyte associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed death ligand-1 (PD-L1). CTLA-4 and PD-1 are negative regulatory receptors expressed on T-cells. ICIs block the negative interactions between T-cells, antigen presenting cells and tumors, allowing positive costimulation to occur and T-cells to become activated \[[@r1]\].

In early trials, treatment with both CTLA-4 and PD1 inhibitors showed a remarkable benefit in promoting durable anti-tumor immune responses, and this success led to the approval by the US Food and Drug Administration (FDA) of the monoclonal antibodies ipilimumab (anti-CTLA4), nivolumab (anti-PD1), pembrolizumab (anti-PD1), atezolizumab (anti-PDL1), avelumab (anti-PDL1) and durvalumab (anti-PDL1) for therapeutic use in a variety of cancers, including melanoma, Non-Small-Cell Lung Cancer (NSCLC), head and neck squamous cell carcinoma, renal cell  carcinoma, Hodgkin lymphoma, bladder cancer, Merkel cell carcinoma and microsatellite instability high or mismatch repair-deficient adult and pediatric solid tumors \[[@r2]\].

Notwithstanding their therapeutic promise, significant toxicity, particularly consisting in Immune-Related Adverse Events (IRAEs), has been observed with both classes of ICIs, with higher rates occurring when PD1-targeted therapy is used in combination with CTLA4-targeted therapy. IRAEs may involve any organ system, including gastrointestinal tract, endocrine glands, skin, liver, cardiovascular and pulmonary systems, and may lead to significant morbidity and, to a lesser extent, mortality (Table **[1](#T1){ref-type="table"}**) \[[@r3]\].

Musculoskeletal and rheumatic diseases are among the less frequently reported IRAEs associated to ICIs treatment, but they are burdened with significant morbidity. In this narrative review, we will summarize the current evidence of rheumatic IRAEs associated with ICIs treatment.

2. METHODS {#sec2}
==========

For the purpose of this narrative review, we conducted a MEDLINE database search for the following words: "arthralgia", "xeroftalmia", "xerostomia", "sicca syndrome", "vasculitis", "myalgia", "myositis", "enthesitis", "arthritis", "systemic lupus erythematosus", "lupus", "polymyalgia rheumatica", "sarcoidosis", "musculoskeletal", "rheumatic" and "anti-PD1", "anti-PDL1", "anti-PD1 antibody", "anti-CTLA4", "CTLA4 antibody", "ipilimumab", "avelumab", "nivolumab", "atezolizumab", "pembrolizumab", "durvalumab", "anti-programmed death 1 monoclonal antibody", "immune checkpoint inhibitor".

3. results {#sec3}
==========

Globally considered, rheumatic and musculoskeletal IRAEs appear to be rarer than other more frequent and burdensome ones, like pneumonitis, hypophysitis and colitis. In a French registry of grade ≥ 2 IRAEs occurring in 908 ICI-treated patients, 21 (2.3%) experienced an event, excluding arthralgia and myalgia, which are more commonly reported and may rather represent a manifestation of the neoplastic disease itself \[[@r4]\]. In another single-center registry of 400 patients treated with ICIs, only 14 (3.5%) developed rheumatic diseases \[[@r5]\].

Tables **[2](#T2){ref-type="table"}** and **[3](#T3){ref-type="table"}** summarize the findings of the rheumatic and musculoskeletal IRAEs occurring in the ICI-treated patient, as reported by observational studies, case series and case reports.

3.1. Arthralgia and Inflammatory Arthritis {#sec3.1}
------------------------------------------

Arthralgia is among the most commonly reported AEs, both in clinical trials, observational studies and case reports. The incidence of arthralgia is around 9-12% and 6-8% for patients receiving pembrolizumab and nivolumab, 5% for patients receiving ipilimumab and 11% for patients receiving the combination therapy of nivolumab and ipilimumab \[[@r6]\].

In a recent systematic review that included 33 clinical trials of all ICIs in different types of cancer, articular pain was the most commonly reported musculoskeletal complaint (1-43% of participants), whereas a true inflammatory arthritis was reported in only five trials, with a prevalence of 1-7% \[[@r1]\].

The same authors described 13 patients with rheumatologic events following nivolumab, ipilimumab or combination therapy. Inflammatory arthritis was seen in 9 patients, with synovitis confirmed in 4 patients by imaging techniques. Some patients required biologic treatment with etanercept, adalimumab or infliximab to achieve mostly a partial response \[[@r7]\].

In another retrospective chart review, the authors reported four cases of inflammatory polyarthritis, four patients with oligoarthritis and two with tenosynovitis. Six of them were ANA positive and two had anti-citrullinated protein (anti-CCP) antibodies. All patients were treated with systemic corticosteroids, even at a small dose, and five patients received steroid-sparing agents. Even so, in some of the patients, the joint symptoms persisted for months \[[@r8]\].

In another retrospective study, conducted in metastatic melanoma treated with pembrolizumab or nivolumab and ipilimumab, 13.3% of patients developed arthralgia. Most frequently, arthralgia involved large joints (shoulders, knees) in a predominantly symmetrical pattern. Only two patients were seropositive for rheumatoid factor and/or anti-CCP antibodies. Ten patients developed a frank inflammatory arthritis. The majority of patients was treated with Non-steroidal Anti-inflammatory Drugs (NSAIDs), 23.1% required additional low-dose corticosteroids and 7.6% of patients received immunosuppressive treatment \[[@r9]\].

Inflammatory arthritis may affect both large and small joints, and may present with different clinical phenotypes, sometimes as oligoarthritis, sometimes as additive arthritis but also as severe polyarthritis \[[@r7], [@r10]\].

A French retrospective study reported that a polyarthritis resembling Rheumatoid Arthritis (RA) developed in six patients receiving ICIs; all six were positive for anti-CCP antibodies and four for rheumatoid factor. The median time to the event after exposure to the drug was 1 month (range 1-9 months). Three patients needed to be treated with disease-modifying anti-rheumatic drugs (DMARDs); the others received corticosteroids or NSAIDs \[[@r11]\].

In the French registry including 908 patients, the prevalence of RA was very low (0.2%), whereas that of non-RA inflammatory polyarthritis was slightly higher (1.2%), reaching 2.5% when ICIs were used in combination \[[@r4]\]. In another single-center registry, polyarthritis was seen in 10 out of 400 patients (2.5%), oligoarthritis in one patient and monoarthritis in another one \[[@r5]\].

Among non-RA inflammatory arthritis, *de-novo* psoriasis and Psoriatic Arthritis (PsA) were reported to be induced by nivolumab in a few patients with advanced lung cancer \[[@r12], [@r13]\]. Some of the authors speculated that the induction of psoriasis may correlate with the therapeutic activity of nivolumab, since the occurrence of the psoriatic skin lesions as well as joint symptoms temporally coincided with the regression of lung cancer lesions \[[@r14]\]. In all the cases the patients received corticosteroids and methotrexate with significant benefit.

Pembrolizumab induced a recurring monoarthritis of both knees in a woman with metastatic melanoma \[[@r15]\] but was also responsible for the acute onset of polyarticular inflammatory arthritis \[[@r16], [@r17]\]. In two of these patients, pembrolizumab caused a severe polyarthritis after 14 and 11 months of therapy, respectively. The first patient had tenosynovitis, synovitis, bone marrow edema, and myositis, whereas the second patient had predominantly synovitis and tenosynovitis. Remission of symptoms was obtained with bisphosphonates and salazopyrin.

In a patient treated with ipilimumab for metastatic melanoma, acute monoarthritis of the knee with a large effusion developed two months after completing ICI therapy and recurred eight months after treatment discontinuation. At both occasions, the patient was given systemic corticosteroid with a moderate benefit. The same patient had pericardial tamponade and bilateral pleural effusions that improved with steroid treatment \[[@r18]\].

A patient treated with nivolumab developed autoimmune uveitis and Jaccoud's arthropathy. The drug was discontinued and uveitis was treated with intraocular steroids with success, but the treatment strategy of the joint disease was not reported \[[@r19]\].

Given the extreme variability of clinical presentations and patterns of inflammatory arthritis in patients receiving ICIs, some authors speculated that one group of patients may develop non-specific arthritis due to the up-regulation of the immune system and another group may develop a more specific form of arthritis, like RA or PsA, based on a genetic or environmental predisposition \[[@r20]\].

3.2. Myalgia and Inflammatory Myositis {#sec3.2}
--------------------------------------

Myalgia was the second most commonly reported musculoskeletal complaint in clinical trials (2-21% of trial participants) \[[@r1]\]. Nevertheless, several cases of true inflammatory myositis have been described, especially with anti-PD1 treatment.

Treatment with nivolumab has been associated with the development of myositis and myocarditis, even of the severe entity, in a number of case reports and case series, especially in Eastern Asia \[[@r21]-[@r25]\]. A patient treated with nivolumab for advanced colon cancer received a diagnosis of myasthenia gravis and myositis for bilateral ptosis, limb and neck weakness, dyspnea and myalgia developing in two weeks. The patient improved after drug withdrawal and prednisolone and intravenous immunoglobulin administration. Another patient developing severe muscle pain, weakness and shortness of breath after the second dose of nivolumab rapidly improved with drug discontinuation and prednisone administration. In the largest retrospective study, among 12 patients with myasthenia gravis, 4 had concomitant myositis and 3 had myocarditis, with 1 of these patients having both.

In these cases of nivolumab-induced myositis, drug withdrawal and corticosteroid with or without further immunosuppressive therapy were usually effective. Respiratory muscle involvement appeared to be the most fearful complication of nivolumab-induced myositis, causing the death of the patient in one case, even though in another case an improvement was seen after drug discontinuation and corticosteroid administration \[[@r26], [@r27]\].

Though IRAEs usually present after some months after drug inception, the onset of severe myositis and myocarditis has been described even after only one dose of nivolumab. This patient improved with corticosteroid treatment, intravenous immunoglobulin and plasma exchange after drug discontinuation \[[@r28]\].

Finally, nivolumab was also found to induce an autoantibody-positive myositis and myocarditis complicated with a new-onset third-degree atrioventricular block \[[@r29]\].

Ipilimumab-induced dermatomyositis has been described in a patient with metastatic melanoma. The clinical picture included erythematosus rash with Gottron's papules and proximal muscle weakness. The drug was discontinued and prednisone 1 mg/kg was started, with minimal clinical response \[[@r30]\].

Another patient developed severe autoimmune myositis following ipilimumab administration, presenting with dysphagia, dysarthria, diffuse muscle weakness and CK elevation. She was treated with intravenous immunoglobulin (400/mg/kg) for ten days and high dose methylprednisolone followed by oral prednisone (1mg/kg daily), with significant benefit and no cancer recurrence \[[@r31]\].

Ipilimumab has also been associated with the development of severe ocular myositis in two patients with metastatic melanoma. In both cases, the condition improved with the administration of methylprednisolone, mycophenolate mofetil and, in one patient, intravenous immunoglobulin \[[@r32]\].

A case of pembrolizumab-induced severe bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm was described in a 78-year-old man with metastatic melanoma. This patient developed progressive dyspnea, bilateral ptosis, neck and limb muscle weakness and dysphagia. Prednisone and plasma exchange did not improve his condition and he died for respiratory failure. Interestingly, the autopsy revealed a diffuse necrotic myositis of the diaphragm and a lymphohistiocytic myocarditis \[[@r33]\].

Other authors reported a case of pembrolizumab-induced myositis, with the muscle biopsy showing multifocal necrosis with adjacent endomysial CD8+ T cell predominant infiltrates, without inclusion bodies. Pembrolizumab was discontinued and the patient was treated first with corticosteroids and then with plasma exchange due to intolerance. The patient experienced a near complete clinical recovery after one month \[[@r34]\]. Among rarer IRAEs, eosinophilic fasciitis has been reported following pembrolizumab treatment in a patient with metastatic melanoma \[[@r35]\].

Myositis was also described in a patient receiving dual treatment with tremelimumab and durvalumab for non-small cell lung cancer. The complication arose in about one month and corticosteroid treatment provided moderate benefit \[[@r10]\].

3.3. SLE and Sicca Syndrome {#sec3.3}
---------------------------

Systemic Lupus Erythematosus (SLE) is an autoimmune disease that may involve several organ systems, including skin, joints, heart, lungs, nervous system and kidneys. In our literature review, SLE was rarely found to be associated with ICIs treatment, particularly with ipilimumab.

The first case of lupus-nephritis induced by ipilimumab was described in 2009 in a patient treated for metastatic melanoma. The kidney biopsy showed immunoglobulin and complement complexes in the mesangial space and the serum anti-double-stranded-DNA antibody test was positive, before treatment with prednisone and ipilimumab discontinuation that eventually improved the nephritis \[[@r36]\].

In a large registry, induction of SLE was reported in only one patient among 524 that experienced an IRAE while on ipilimumab treatment \[[@r37]\].

A lupus-like cutaneous reaction in the setting of pembrolizumab therapy for metastatic melanoma was described \[[@r38]\], as well as in a patient receiving nivolumab for metastatic lung cancer \[[@r39]\]. In the latter case, erythematous and non-pruritic papules developed, with histological findings suggestive of a lupus-like drug reaction. The skin rash improved after one month without further treatment other than nivolumab discontinuation.

Dry eyes and dry mouth have been reported as mild AEs in some ICIs clinical trials, with an incidence ranging from 3-24% \[[@r1], [@r40]\]. In a large French registry reporting only grade ≥ 2 IRAEs occurring in ICI-treated patients, the prevalence of true Sjogren's syndrome was 0.3% \[[@r4]\].

Four out of five patients with sicca syndrome described in a retrospective study had dry mouth without eye involvement following nivolumab, atezolizumab or combination treatment. ANA was positive in two of the five patients, and SSA was positive in one \[[@r10]\].

In another case series, four patients presented sicca symptoms with severe salivary hypofunction developing on nivolumab, ipilimumab or combination therapy. On ultrasound imaging, one patient had discrete hypoechoic foci occupying more than 50% of her parotid and submandibular glands, as it is usually seen in Sjogren's syndrome. One patient had also pneumonitis and another had interstitial nephritis and colitis. Three of four sicca patients had positive ANA; one patient had low titre La/SSB antibodies; none of the patients had Ro/SSA antibodies \[[@r7]\].

A patient with metastatic parotid carcinoma developed a sicca syndrome associated with a skin rash on both hands that was identified as Gourgerot-Sjogren like syndrome \[[@r41]\].

3.4. Vasculitis {#sec3.4}
---------------

Isolated cases of vasculitis have been reported following the administration of ICIs (ipilimumab in 3 cases, pembrolizumab in 2 cases) in a large biologic drug registry \[[@r37]\]. Most cases of vasculitis induced by biologics present with isolated cutaneous or neurological (peripheral neuropathy) involvement, and systemic vasculitis appear to be rare. Only two clinical trials of ICIs reported the onset of vasculitis among patients receiving these compounds and in one case a giant cell arteritis was diagnosed \[[@r1]\].

Among isolated vasculitis, cases of peripheral neuropathy due to histologically proven small vessel vasculitis have been reported. One was induced by pembrolizumab in a 53-year-old woman with seropositive RA and metastatic melanoma. She was treated with high-dose corticosteroids, followed by a gradual tapering, with a complete functional recovery over 6-months and minimal residual paraesthesia \[[@r42]\].

Even though not all cases of asymmetric polyradiculoneuropathy described in patients on ICIs are secondary to vasculitis, an aspecific microvasculopathy underlying the pathogenesis of the nerve damage has been occasionally described \[[@r43]\], as well as an acral vascular syndrome presenting with progressive erythema, paresthesia and fingertip pain, but without histological evidence of vasculitis \[[@r44]\].

Another isolated form of vasculitis involved the uterine circulation, with lymphocytic infiltration and focal fibrin deposition. This patient was receiving ipilimumab for metastatic melanoma and presented with an asymptomatic uterine mass \[[@r45]\].

3.5. Polymyalgia Rheumatica {#sec3.5}
---------------------------

Polymyalgia Rheumatica (PMR) almost invariably responds to systemic corticosteroids, even if occurring in patients receiving ICIs.

Some authors reported the development of PMR in two patients with metastatic melanoma being treated with ipilimumab. In one case, a biopsy of the right temporal artery was performed, showing active arteritis, intimal proliferation, and disruption of the internal elastic lamina. Both patients had a brisk response to corticosteroids, with improvement in symptoms and indices of inflammation \[[@r46]\].

In a French retrospective study, PMR was diagnosed in four patients treated with pembrolizumab and nivolumab ± ipilimumab, and all patients responded to treatment with corticosteroids \[[@r11]\].

Another French group reported the development of PMR in a patient with non--small cell lung cancer after 13 cycles of nivolumab, with a good response to corticosteroid therapy \[[@r47]\].

In a case series from the Cleveland Clinic, 3 out of 15 patients evaluated at the Rheumatology Unit had clinical characteristics compatible with PMR including pain and stiffness involving the shoulders, hips and neck, with associated severe morning stiffness. None of them had symptoms concerning for giant cell arteritis \[[@r10]\]. Other patients receiving nivolumab and pembrolizumab developed typical features of PMR that responded well to corticosteroid treatment \[[@r48], [@r49]\].

Finally, other authors described a variant of PMR, called remitting seronegative symmetrical synovitis with pitting edema syndrome, to be induced by nivolumab in an 80-year-old man with metastatic melanoma \[[@r50]\].

3.6. Sarcoidosis {#sec3.6}
----------------

Several cases of new-onset sarcoidosis were reported in patients being treated with ICIs for metastatic melanoma, including those from a large biologic drugs registry in which sarcoidosis complicated treatment with ipilimumab (13 cases), nivolumab (4 cases) and pembrolizumab (3 cases) \[[@r37]\]. In another retrospective study, 5% out of 147 patients undergoing ipilimumab treatment for melanoma developed sarcoid-like lymphadenopathy after a median interval time of 3.2 months from the start of ipilimumab. The majority of patients had mediastinal and hilar lymphadenopathy except for one patient who had a coexistent intra-abdominal lymphadenopathy \[[@r51]\]. Conversely, in a single center registry, the prevalence of sarcoidosis in patients receiving ICIs was very low (0.2%) \[[@r4]\].

Notably, some authors observed that in a patient with ICI-induced sarcoidosis the suspension of the drug alone achieved the complete resolution of the metabolically active lymph nodes without the need of additional steroid treatment \[[@r52]\]. Recently, some authors reviewed the cases of 26 patients developing granulomatous/sarcoid-like lesions associated with ICIs. Treatment was discontinued in 38% of patients and only 44% of the patients were treated with systemic steroids. Almost all of the patients demonstrated either resolution or improvement of granulomatous/sarcoid-like lesions irrespective of medical intervention \[[@r53]\].

In other three cases of ICI-related sarcoidosis-like lymphadenopathy, two occurring during adjuvant ipilimumab for stage III surgically resected melanoma and one during pembrolizumab for metastatic melanoma, histopathological examination revealed non-caseating granulomas. Two of the patients improved with drug discontinuation alone without the need of corticosteroid treatment \[[@r54]\]. Another melanoma patient developed sarcoidosis with bilateral anterior uveitis \[[@r55]\].

Several other reports confirm that sarcoid-like reactions induced by ICIs are common and often do not require other treatment than drug discontinuation \[[@r56]-[@r58]\], though in some cases ICI-treatment may be continued without a significant impact on the patient's clinical conditions \[[@r59], [@r60]\].

4. DISCUSSION {#sec4}
=============

Our review suggests that, though rare, musculoskeletal and rheumatic diseases appear to be associated with ICI-treatment and demand a prompt recognition to avoid further impact on morbidity and mortality for cancer patients. The approach to the management of these patients may require a tight cooperation between the oncologist and the rheumatologist, that should balance risks and benefits of continuing or withdrawing anti-tumor treatment and evaluate the need for a systemic anti-inflammatory or immunomodulating therapy.

It is difficult to estimate the true incidence and prevalence of musculoskeletal AEs in patients receiving ICIs, given that most of the observational studies are retrospective. Overall, rheumatic complications appear to involve no more than 10% of the ICIs-treated patients. Most of the AEs are mild-to-moderate, except for the more severe forms of myositis that may lead to death due to respiratory involvement.

There are different treatment options for musculoskeletal AEs that vary with the extent and the severity of the disease. Inflammatory arthritis may respond to relatively short courses of NSAIDs or glucocorticoids, but some of the patients may need DMARDs and/or biologic treatment due to refractoriness or disease recurrence upon treatment tapering or discontinuation \[[@r61], [@r62]\]. PMR usually responds to glucocorticoid treatment that may be tapered as it is usually done in non-cancer patients. Severe forms of myositis may require intravenous immunoglobulin and plasma exchange in addition to corticosteroid treatment. Sarcoidosis and sarcoid-like reactions are usually managed with treatment discontinuation and glucocorticoids.

Even if mild AEs may be managed with drug discontinuation alone, continuing ICI treatment is possible and appears to be safe. Rather, patients that experienced rheumatic AEs while on ICIs showed a higher tumor response rate compared to those who did not \[[@r61]\]. There are several studies reporting the positive association of the tumor response rate with the incidence of different IRAEs in cancer patients \[[@r63]\].

Since most of the clinical trials of ICIs excluded patients with a preexisting autoimmune disease, little is known about how these drugs may affect this group of patients. Available data on immunotherapy in melanoma patients with preexisting autoimmune diseases are mostly retrospective. Among 30 patients with a variety of autoimmune diseases (from RA to inflammatory bowel diseases) treated with ipilimumab for melanoma, only 8 (27%) had an exacerbation of their autoimmune disease; all flares were medically treated and were observed within the first 6 weeks after the beginning of therapy \[[@r64]\]. A similar retrospective study analyzed melanoma patients who were treated with pembrolizumab or nivolumab after previous failed or intolerant treatment with ipilimumab. Twenty (38%) patients developed a flare of their autoimmune disorder requiring immunosuppression, including seven out of 13 patients with RA. The majority of the flares were relatively mild and only two patients required discontinuation of anti-PD1 treatment \[[@r65]\].

As far as we know, ICIs administration in a patient with a preexisting autoimmune condition is safe enough to warrant treatment. Rheumatic or autoimmune disease flares can usually be managed only with steroids, with or without discontinuation of the treatment drug, though rarely they may require immunosuppressive treatment \[[@r66], [@r67]\].

CONCLUSION
==========

Immune checkpoint inhibitor treatment has been a breakthrough option in several metastatic cancers. As their use is increasing, there is gathering evidence that they may induce rheumatic and musculoskeletal disorders or cause disease flares in patients with a preexisting autoimmune disorder. A rapid recognition and a prompt treatment, possibly with a rheumatologist referral, may help to improve the quality of life of these complicated cancer patients.
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###### 

Therapeutic indications and commonly reported adverse events of the main ICIs.

  **Drug**        **ICI Target**   **Therapeutic Indications**                                                                                                                                     **Commonly Reported Adverse Events**
  --------------- ---------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------
  Ipilimumab      CTLA-4           Metastatic melanoma                                                                                                                                             Fatigue, rash, colitis (+), hepatotoxicity, pneumonitis (-), hypophysitis (+), hypothyroidism
  Pembrolizumab   PD-1             Metastatic melanoma, NSCLC, Head and neck cancer, Hodgkin's lymphoma, urothelial carcinoma, gastric cancer                                                      Fatigue, rash, colitis (-), hepatotoxicity, pneumonitis (+), hypophysitis (-), hypothyroidism
  Nivolumab       PD-1             Metastatic melanoma, NSCLC, Renal cell carcinoma, Hodgkin's lymphoma, head and neck cancer, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma   Fatigue, rash, colitis (-), hepatotoxicity, pneumonitis (+), hypophysitis (-), hypothyroidism
  Atezolizumab    PD-L1            NSCLC, locally advanced or metastatic urothelial carcinoma                                                                                                      Fatigue, rash, hepatotoxicity, hypophysitis (+), hypothyroidism

###### 

Published case reports and case series of musculoskeletal IRAEs induced by ICIs.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **References**                   **Drug**                                           **Indication**                                                              **Clinical Presentation**                                                                                                                                                                                                                                                                                                                                                                              **Withdrawal of Drug**                                                                    **Treatment and Outcome**                                                                                                                                                                                                                                                                                                          **Type of Study**
  -------------------------------- -------------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------
  Hunter 2009 \[[@r31]\]           Ipilimumab                                         Melanoma                                                                    Dysphagia, dysarthria, diffuse muscle weakness, elevation of CK.\                                                                                                                                                                                                                                                                                                                                      No (symptoms appeared after the end of therapy)                                           Corticosteroid and intravenous Ig\                                                                                                                                                                                                                                                                                                 Case report
                                                                                                                                                                  Diagnosis of acute polymyositis                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Response to therapy and healing of melanoma                                                                                                                                                                                                                                                                                        

  Fadel 2009 \[[@r36]\]            Ipilimumab                                         Melanoma                                                                    After two injections, the patient developed signs and symptoms of lupus nephritis                                                                                                                                                                                                                                                                                                                      Yes                                                                                       Corticosteroid therapy with clinical improvement                                                                                                                                                                                                                                                                                   Case report

  Manousakis 2013 \[[@r43]\]       Ipilimumab                                         Metastatic melanoma                                                         Asymmetric, severe weakness involving all limbs, respiration, and cranial nerves, which was progressive over 2 weeks. EMG/NCS showed an axonal polyradiculoneuropathy with multifocal motor conduction blocks.\                                                                                                                                                                                        Yes                                                                                       Improvement over months without further treatment                                                                                                                                                                                                                                                                                  Case report
                                                                                                                                                                  Nerve pathology showed inflammation around the endoneurial microvessels and subperineurial edema and inflammation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Minor 2013 \[[@r45]\]            Ipilimumab                                         Melanoma                                                                    Uterine lymphocytic vasculitis presenting with a mass in uterus and pelvic lymphadenopathy                                                                                                                                                                                                                                                                                                             No (therapy just finished)                                                                Hysterectomy due to concern for malignancy\                                                                                                                                                                                                                                                                                        Case report
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   No further treatment                                                                                                                                                                                                                                                                                                               

  Goldstein 2014 \[[@r46]\]        Ipilimumab                                         Melanoma                                                                    Two patients developed polymyalgia rheumatica\                                                                                                                                                                                                                                                                                                                                                         Yes                                                                                       High dose corticosteroid therapy\                                                                                                                                                                                                                                                                                                  Case series
                                                                                                                                                                  w/o giant cell arteritis                                                                                                                                                                                                                                                                                                                                                                                                                                                                         After six months one patient died                                                                                                                                                                                                                                                                                                  

  Chan 2015 \[[@r17]\]             Pembrolizumab                                      Melanoma                                                                    First case: Knee arthritis\                                                                                                                                                                                                                                                                                                                                                                            Yes\                                                                                      First case: Steroid therapy with resolution of symptoms\                                                                                                                                                                                                                                                                           Case series
                                                                                                                                                                  Second case: Polyarthritis and myalgia diagnosed as seronegative inflammatory arthritis                                                                                                                                                                                                                                                                                                                (in the first case drug was restarted after symptoms resolution)                          Second case: naproxen, hydroxychloroquine and paracetamol                                                                                                                                                                                                                                                                          

  Sheik 2015 \[[@r30]\]            Ipilimumab                                         Melanoma                                                                    Erythematous rash with Gottron's papules and proximal muscle weakness\                                                                                                                                                                                                                                                                                                                                 Yes                                                                                       Prednisone 80 mg daily tapered over 8 weeks.\                                                                                                                                                                                                                                                                                      Case report
                                                                                                                                                                  Diagnosis: dermatomyositis                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Only a minimal clinical response was achieved.                                                                                                                                                                                                                                                                                     

  Yoshioka 2015 \[[@r27]\]         Nivolumab                                          Melanoma                                                                    Shortness of breath with CPK elevation\                                                                                                                                                                                                                                                                                                                                                                Yes                                                                                       Complete recovery after several weeks                                                                                                                                                                                                                                                                                              Case report
                                                                                                                                                                  Diagnosis: Myositis complicated by respiratory distress                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Garel 2016 \[[@r48]\]            Pembrolizumab                                      Metastatic melanoma                                                         Two patients presenting with pain of the shoulders and hip girdles, morning stiffness\                                                                                                                                                                                                                                                                                                                 No (partial in one case)                                                                  Fast improvement 48 hours after the beginning of oral prednisone.\                                                                                                                                                                                                                                                                 Case report
                                                                                                                                                                  Diagnosis: Polymyalgia rheumatica                                                                                                                                                                                                                                                                                                                                                                                                                                                                Disease remission at one month                                                                                                                                                                                                                                                                                                     

  De Velasco 2016 \[[@r19]\]       Nivolumab                                          Metastatic clear cell renal cell carcinoma                                  Autoimmune uveitis and Jaccoud's arthropathy                                                                                                                                                                                                                                                                                                                                                           Yes                                                                                       Improvement of uveitis with corticosteroid treatment.\                                                                                                                                                                                                                                                                             Case report
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Not reported the outcome of arthropathy                                                                                                                                                                                                                                                                                            

  Khoja 2016 \[[@r35]\]            Pembrolizumab                                      Melanoma                                                                    Eosinophilic fasciitis                                                                                                                                                                                                                                                                                                                                                                                 No (symptoms appeared after the end of therapy)                                           Corticosteroid therapy with clinical improvement                                                                                                                                                                                                                                                                                   Case report

  **References**                   **Drug**                                           **Indication**                                                              **Clinical Presentation**                                                                                                                                                                                                                                                                                                                                                                              **Withdrawal of Drug**                                                                    **Treatment and Outcome**                                                                                                                                                                                                                                                                                                          **Type of Study**

  Law-ping-man 2016 \[[@r14]\]     Nivolumab                                          NSCLC                                                                       After eight infusion of drug, the patient developed psoriatic arthritis                                                                                                                                                                                                                                                                                                                                Yes (for 4 weeks)                                                                         Corticosteroid and MTX therapy with improvement of skin lesions and arthritis and subsequent stop of steroid and MTX                                                                                                                                                                                                               Case report

  Kimura 2016 \[[@r28]\]           Nivolumab                                          Melanoma                                                                    Two months after the first dose acute polymyositis developed                                                                                                                                                                                                                                                                                                                                           Yes                                                                                       Corticosteroids, intravenous immunoglobulin, PLEX with significant benefit                                                                                                                                                                                                                                                         Case report

  Schmutz 2016 \[[@r12]\]          Nivolumab                                          NSCLC                                                                       After eight infusions, the patient developed psoriatic arthritis                                                                                                                                                                                                                                                                                                                                       Yes                                                                                       Corticosteroid and MTX were started\                                                                                                                                                                                                                                                                                               Case report
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Nivolumab was restarted after response of skin lesions                                                                                                                                                                                                                                                                             

  Fox 2016 \[[@r25]\]              Nivolumab                                          Melanoma                                                                    After the second dose of drug, severe muscle pain, difficulty breathing, shortness of breath, and an inability to lift the legs with CPK elevation\                                                                                                                                                                                                                                                    Yes                                                                                       Corticosteroids with normalization of CK within one week                                                                                                                                                                                                                                                                           Case report
                                                                                                                                                                  Diagnosis: Myositis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Vallet 2016 \[[@r34]\]           Pembrolizumab                                      Melanoma                                                                    After two injections, proximal bilateral limb weakness and dysphonia with CPK elevation\                                                                                                                                                                                                                                                                                                               Yes                                                                                       Corticosteroids followed by two cycles of PLEX, followed by one PLEX per week for 3 weeks\                                                                                                                                                                                                                                         Case report
                                                                                                                                                                  Diagnosis: Myositis                                                                                                                                                                                                                                                                                                                                                                                                                                                                              One month after the onset of symptoms, patient had a near complete clinical recovery. No relapses at 3 months of follow-up                                                                                                                                                                                                         

  Konoeda 2017 \[[@r21]\]          Nivolumab                                          Advanced colon cancer                                                       Bilateral ptosis, limb and neck weakness, dyspnea, and myalgia in two weeks. Diagnosis of myasthenia gravis and myositis                                                                                                                                                                                                                                                                               Yes                                                                                       Oral prednisolone, intravenous immunoglobulin and plasma exchange with noninvasive positive-pressure ventilation                                                                                                                                                                                                                   Case report

  Haddox 2017 \[[@r33]\]           Pembrolizumab                                      Melanoma                                                                    Progressive dysarthria, bilateral ptosis, neck weakness, dysphagia, diffuse myalgia, and mild proximal muscle weakness in both the upper and lower extremities.\                                                                                                                                                                                                                                       Yes                                                                                       Prednisone and PLEX (three sessions) were started but patient continued to deteriorate and died for respiratory failure. An autopsy was performed, which revealed diffuse necrotic myositis of the diaphragm and lymphohistiocytic myocarditis                                                                                     Case report
                                                                                                                                                                  Diagnosis of immune-mediated necrotizing myopathy over a NMJ disorder                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Teyssonneau 2017 \[[@r41]\]      Pembrolizumab                                      Left parotid acinic cell carcinoma with adrenal gland and lung metastases   Dry-eye syndrome, conjunctival hyperemia, xerostomia and skin rash on both hands identified as Gougerot-Sjogren like syndrome                                                                                                                                                                                                                                                                          No                                                                                        Daily dose of 10 mg prednisone, betamethasone cream for the hands, artificial tear drops and artificial saliva. For dry-eye syndrome and the xerostomia, which significantly affected the patient's daily life, treatment with pilocarpine                                                                                         Case report

  Behling 2017 \[[@r29]\]          Nivolumab                                          Melanoma                                                                    Moderate pain in the proximal muscle groups of the upper limbs and a slight worsening of a pre-existing dyspnea (started 10 days after the first infusion). Three days later dyspnea, dysphagia, and worsened muscle pain lead to hospitalization. Increase of CPK, myoglobin, troponin I, ANA positive\                                                                                               No                                                                                        Immunosuppressive therapy with iv prednisone\                                                                                                                                                                                                                                                                                      Case report
                                                                                                                                                                  Diagnosis of autoimmune-induced myositis                                                                                                                                                                                                                                                                                                                                                                                                                                                         After four days of hospitalization, a third-degree atrioventricular block with a bradycardia of 44 bpm and a systolic blood pressure up to 200 mmHg developed. The patient died after 26 days of treatment                                                                                                                         

  **References**                   **Drug**                                           **Indication**                                                              **Clinical Presentation**                                                                                                                                                                                                                                                                                                                                                                              **Withdrawal of Drug**                                                                    **Treatment and Outcome**                                                                                                                                                                                                                                                                                                          **Type of Study**

  Bernier 2017 \[[@r47]\]          Nivolumab                                          NSCLC                                                                       Diffuse joint pain that occurred suddenly.\                                                                                                                                                                                                                                                                                                                                                            Yes\                                                                                      Good response to corticosteroid therapy                                                                                                                                                                                                                                                                                            Case report
                                                                                                                                                                  Diagnosis of polymyalgia rheumatica                                                                                                                                                                                                                                                                                                                                                                    (Drug was restarted after resolution of joint pain in association with steroid therapy)                                                                                                                                                                                                                                                                                                                                      

  Chen 2017 \[[@r26]\]             Nivolumab                                          NSCLC                                                                       Ptosis, diplopia, drop head, and general weakness 5 days after a third drug infusion conducted to a diagnosis of nivolumab-related myasthenia and myositis                                                                                                                                                                                                                                             Yes                                                                                       Steroid treatment with methylprednisolone 1mg/kg/d and pyridostigmine 60mg twice a day was administered beginning at admission; however, the patient's condition progressively worsened, despite treatment. Respiratory failure developed 2 weeks after admission. The patient died on day 27 after the third nivolumab infusion   Case report

  Dasanu 2017 \[[@r18]\]           Ipilimumab                                         Melanoma                                                                    Swelling and pain involving the right knee with signs of synovial inflammation and an important joint effusion; moderate bilateral pleural effusions and enlarged heard silhouette; large pericardial effusion                                                                                                                                                                                         Just completed                                                                            Steroid therapy was initiated with remarkable clinical improvement over the next 24h and then was tapered over the next six weeks with resolution of pericardial and pleural effusions two weeks later.\                                                                                                                           Case report
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Eight months after completing ipilimumab therapy, the right knee effusion re-accumulated and prednisone was restarted                                                                                                                                                                                                              

  Gauci 2017 \[[@r50]\]            Nivolumab                                          Melanoma                                                                    After three drug infusions, the patient developed a variant of polymyalgia rheumatica                                                                                                                                                                                                                                                                                                                  Yes                                                                                       Corticosteroid therapy. After achieving remission, nivolumab was recommenced without any flare of arthritis                                                                                                                                                                                                                        Case report

  Liu 2017 \[[@r39]\]              Nivolumab                                          NSCLC                                                                       After five months of nivolumab therapy, the patient developed subacute cutaneous lupus erythematosus                                                                                                                                                                                                                                                                                                   Yes                                                                                       Corticosteroids, hydroxychloroquine, aspirin with improvement.\                                                                                                                                                                                                                                                                    Case report
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Nivolumab was restarted after 5 months                                                                                                                                                                                                                                                                                             

  Mahmoud 2017 \[[@r15]\]          Pembrolizumab                                      Melanoma                                                                    Knee inflammatory synovitis                                                                                                                                                                                                                                                                                                                                                                            No                                                                                        Prednisone and infliximab                                                                                                                                                                                                                                                                                                          Case report

  Pushkarevskaya 2017 \[[@r32]\]   Ipilimumab                                         Melanoma                                                                    First case: After four months diagnosis of ocular myositis\                                                                                                                                                                                                                                                                                                                                            Yes                                                                                       First case: Corticosteroid therapy and mycophenolate mofetil and immunoglobulin\                                                                                                                                                                                                                                                   Case report
                                                                                                                                                                  Second case: After two cycles of drug diagnosis of ocular myositis                                                                                                                                                                                                                                                                                                                                                                                                                               Second case: Corticosteroid therapy and mycophenolate mofetil.\                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Both resolution of myositis                                                                                                                                                                                                                                                                                                        

  Ruiz-Bañobre 2017 \[[@r13]\]     Nivolumab                                          NSCLC                                                                       Diagnosis of psoriatic arthritis after the 11^th^ course of nivolumab                                                                                                                                                                                                                                                                                                                                  No                                                                                        Corticosteroid and NSAIDS therapy and then MTX with nivolumab.\                                                                                                                                                                                                                                                                    Case report
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Minimal disease activity was achieved                                                                                                                                                                                                                                                                                              

  Saini 2017 \[[@r24]\]            Nivolumab                                          Hodgkin lymphoma and then acute myeloid leukemia                            Diffuse edema with subsequent diagnosis of autoimmune myositis                                                                                                                                                                                                                                                                                                                                         No                                                                                        Corticosteroid therapy.\                                                                                                                                                                                                                                                                                                           Case report
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   The patient died after six months from diagnosis                                                                                                                                                                                                                                                                                   

  Salmon 2017 \[[@r16]\]           Pembrolizumab                                      Melanoma                                                                    After nine infusions, the patient developed polyarthritis and fever                                                                                                                                                                                                                                                                                                                                    No                                                                                        Corticosteroid therapy and then MTX were prescribed with moderate benefit                                                                                                                                                                                                                                                          Case report

  **References**                   **Drug**                                           **Indication**                                                              **Clinical Presentation**                                                                                                                                                                                                                                                                                                                                                                              **Withdrawal of Drug**                                                                    **Treatment and Outcome**                                                                                                                                                                                                                                                                                                          **Type of Study**

  Gambichler 2017 \[[@r44]\]       Nivolumab + ipilimumab                             Melanoma                                                                    After three weeks, the patient developed progressive erythema, paresthesia and pain on the fingertips of both hands\                                                                                                                                                                                                                                                                                   No                                                                                        Treatment with corticosteroids and prostacyclin.\                                                                                                                                                                                                                                                                                  Case report
                                                                                                                                                                  Diagnosis: Acral vascular syndrome\                                                                                                                                                                                                                                                                                                                                                                                                                                                              The patient died for cancer progression                                                                                                                                                                                                                                                                                            
                                                                                                                                                                  Histopathology did not reveal evidence for vasculitis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Firwana 2017 \[[@r54]\]          First case: Ipilimumab\                            Melanoma                                                                    First case: Tender retroauricular, occipital, cervical, and axillary lymphadenopathy. PET CT showed substantial bilateral cervical, axillary, hilar, mediastinal, iliac, and inguinal lymphadenopathy\                                                                                                                                                                                                 First case: Yes\                                                                          First case: No corticosteroids were prescribed.\                                                                                                                                                                                                                                                                                   Case series
                                   Second case: Ipilimumab\                                                                                                       Second case: PET CT showed diffuse hilar and mediastinal lymphadenopathy. Pathology revealed multiple poorly formed epithelioid granulomas with multinucleated giant cells, focal necrotic debris, and abundant small lymphocytes, but no evidence of melanoma.\                                                                                                                                       Second case: Not reported\                                                                Follow-up PET CT obtained three months later showed complete resolution of the lymphadenopathy\                                                                                                                                                                                                                                    
                                   Third case: Ipilimumab followed by pembrolizumab                                                                               Third case: The patient developed a granulomatous skin lesion on right forearm. A biopsy of the lymph node confirmed a systemic granulomatous process                                                                                                                                                                                                                                                  Third case: Yes, but not immediately                                                      Second case: Not reported\                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Third case: Symptoms resolved spontaneously in few weeks without any treatment. PET-CT imaging obtained two months after stopping pembrolizumab showed stable lymphadenopathy                                                                                                                                                      

  Lainez 2017 \[[@r59]\]           Nivolumab                                          NSCLC                                                                       After 8 injections of nivolumab, a new CT and PET scan revealed massive growth and increase in metabolism of hilar and mediastinal lymph nodes.\                                                                                                                                                                                                                                                       No                                                                                        Stability of disease at 12 months without treatment                                                                                                                                                                                                                                                                                Case report
                                                                                                                                                                  EBUS-TBNA showed an epithelioid cell reaction compatible with sarcoidosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Reuss 2017 \[[@r60]\]            Nivolumab plus ipilimumab                          Metastatic melanoma                                                         PET-CT scan revealed new supraclavicular, mediastinal, right hilar and left iliac adenopathy, as well as subcutaneous left pretibial and right calf nodules. Histology showed non-caseating granulomas.\                                                                                                                                                                                               Partial: Nivolumab monotherapy was maintained                                             Stable disease without treatment                                                                                                                                                                                                                                                                                                   Case report
                                                                                                                                                                  Diagnosis of sarcoidosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Reddy 2017 \[[@r58]\]            Ipilimumab plus pembrolizumab (1 case)\            Metastatic melanoma                                                         Mediastinal and hilar lymphadenopathy and multiple subcentimeter pulmonary nodules in the bilateral upper and lower lobes of the lungs and skin lesion consistent with sarcoidosis (1 case)\                                                                                                                                                                                                           Yes (temporary withdrawal)                                                                Improvement with corticosteroids                                                                                                                                                                                                                                                                                                   Case report
                                   Ipilimumab plus nivolumab (1 case)                                                                                             Mediastinal and hilar lymphadenopathy as well as mild nonspecific nodularity in the right lower lung and several subcutaneous nodules that on biopsy showed a granulomatous infiltrate within the dermis and subcutaneous fat, composed of well-formed noncaseating granulomas with multinucleated giant cells and scattered lymphocytes. The final diagnosis was sarcoidosis                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  **References**                   **Drug**                                           **Indication**                                                              **Clinical Presentation**                                                                                                                                                                                                                                                                                                                                                                              **Withdrawal of Drug**                                                                    **Treatment and Outcome**                                                                                                                                                                                                                                                                                                          **Type of Study**

  Lomax 2017 \[[@r57]\]            One case: Nivolumab vs ipilimumab\                 Melanoma                                                                    Hilar and mediastinal adenopathy and subcutaneous nodules.\                                                                                                                                                                                                                                                                                                                                            Yes (2 cases)\                                                                            No treatment (1 case) with improvement\                                                                                                                                                                                                                                                                                            Case series
                                   Two cases: Pembrolizumab                                                                                                       Diagnosis of sarcoidosis                                                                                                                                                                                                                                                                                                                                                                               No (1 case)                                                                               Corticosteroid therapy (2 cases) with improvement                                                                                                                                                                                                                                                                                  

  Zhang 2017 \[[@r56]\]            Nivolumab                                          Metastatic clear cell renal carcinoma                                       PET CT showed asymptomatic bilateral mediastinal and hilar lymphadenopathy.\                                                                                                                                                                                                                                                                                                                           Not reported                                                                              Not reported                                                                                                                                                                                                                                                                                                                       Case report
                                                                                                                                                                  Histopathology examination revealed epithelioid granulomas consistent with sarcoidosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Nakamagoe 2017 \[[@r49]\]        Nivolumab                                          Metastatic melanoma                                                         After 2 months, generalized joint pain and weakness of proximal muscles developed.\                                                                                                                                                                                                                                                                                                                    Yes                                                                                       Oral corticosteroid with marked improvement with 24 hours and resolution of symptoms after 3 weeks                                                                                                                                                                                                                                 Case report
                                                                                                                                                                  A diagnosis of polymyalgia rheumatica was made                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Tan 2017 \[[@r23]\]              Nivolumab                                          NSCLC                                                                       Immune-mediated myasthenia gravis and myositis with respiratory failure                                                                                                                                                                                                                                                                                                                                No                                                                                        Treatment with pyridostigmine, methylprednisolone (1 g daily for 3 days), and immune globulin (400 mg/kg/d for 5 days) with benefit                                                                                                                                                                                                Case report

  Aya 2017 \[[@r42]\]              Pembrolizumab                                      Melanoma                                                                    Bilateral paresthesia in glove and stocking distribution that rapidly progressed with severe weakness in her lower limbs and diplopia (6th cranial nerve palsy). Electromyography and nerve conduction study showed a moderate sensory peripheral polyneuropathy.\                                                                                                                                     Yes                                                                                       Pulses of corticosteroids, then oral prednisone at 1 mg/kg slowly tapered over 6 months until 5 mg/day and then discontinued.\                                                                                                                                                                                                     Case report
                                                                                                                                                                  Muscle and nerve biopsy showed some angulated atrophic muscle fibers and perivascular infiltration of mononuclear cells of small endoneural vessels                                                                                                                                                                                                                                                                                                                                              Complete functional recovery over 6 months.                                                                                                                                                                                                                                                                                        

  Nandavaram 2017 \[[@r52]\]       Ipilimumab                                         Melanoma                                                                    Asymptomatic mediastinal and hilar nodes bilaterally.\                                                                                                                                                                                                                                                                                                                                                 Yes                                                                                       Improvement without further treatment                                                                                                                                                                                                                                                                                              Case report
                                                                                                                                                                  Histopathological examination revealed non-caseating granulomatous lymphadenitis characterized by aggregates of epithelioid macrophages consistent with sarcoidosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Kim 2017 \[[@r62]\]              Ipilimumab\                                        Metastatic melanoma                                                         Three cases of symmetric polyarthritis involving small joints that developed between the second and the fourth infusion of the drug                                                                                                                                                                                                                                                                    No                                                                                        All patients received corticosteroids and IL-6 receptor antagonist (tocilizumab) with articular response.\                                                                                                                                                                                                                         Case series
                                   Pembrolizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   One patient discontinued tocilizumab because of adrenal insufficiency                                                                                                                                                                                                                                                              

  Shao 2018 \[[@r38]\]             Pembrolizumab                                      Melanoma                                                                    Erythematous and non-pruritic eruption of edematous papules coalescing into plaques on his back, chest, lateral arms, thighs, and abdomen\                                                                                                                                                                                                                                                             Yes                                                                                       Within one month, the rash completely resolved without use of topical steroids or other topical medications                                                                                                                                                                                                                        Case report
                                                                                                                                                                  Histological findings of papules were interpreted as a lupus-like medication reaction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  **References**                   **Drug**                                           **Indication**                                                              **Clinical Presentation**                                                                                                                                                                                                                                                                                                                                                                              **Withdrawal of Drug**                                                                    **Treatment and Outcome**                                                                                                                                                                                                                                                                                                          **Type of Study**

  Yatim 2018 \[[@r55]\]            Pembrolizumab                                      Melanoma                                                                    PET/CT-scan found at the thoracic level bilateral new multiple pleural and parenchymal hypermetabolic lesions and hypermetabolic enlarged bilateral hilar lymph nodes and multiple subcutaneous highly metabolic active nodules appeared on the left flank, right leg, hypogastric region and on a laparotomy surgical scar. Bilateral anterior uveitis was present. The patient was diagnosed with\   No (after the end of therapy)                                                             No treatment. Three months later another PET/CT-scan showed complete regression of the hypermetabolic sarcoidosis lesions                                                                                                                                                                                                          Case report
                                                                                                                                                                  sarcoidosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Published observational studies reporting the incidence of musculoskeletal IRAEs in ICI-treated patients.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **References**                 **Drugs**                                          **Indications**                          **Clinical Presentation**                                                                                                                                                                                                                                                                                                      **Withdrawal of Drugs**    **Treatment and Outcome**                                                                                                                                                  **Type of Study**
  ------------------------------ -------------------------------------------------- ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------
  Smith 2017 \[[@r8]\]           Nivolumab\                                         Melanoma\                                Ten patients, seven treated with combination therapy and 3 in monotherapy\                                                                                                                                                                                                                                                     No (except one case)       All patients were treated with systemic corticosteroids for their arthritis or tenosynovitis\                                                                              Retrospective study
                                 Pembrolizumab\                                     NSCLC\                                   4 cases of polyarthritis\                                                                                                                                                                                                                                                                                                                                 Three patients were started on DMARDs and one patient required infliximab to allow tapering of steroids\                                                                   
                                 Ipilizumab\                                        Anal cancer\                             4 cases of oligoarthritis\                                                                                                                                                                                                                                                                                                                                Six of the patients had resolution of musculoskeletal symptoms and discontinued treatment an average of 9.2 months after the last dose of immunotherapy\                   
                                 Tremelimumab                                       Cervical cancer\                         2 cases of tenosynovitis\                                                                                                                                                                                                                                                                                                                                 Four patients continued to be treated for their arthritis at the time of last rheumatology\                                                                                
                                                                                    Merkel cell carcinoma\                   of which:\                                                                                                                                                                                                                                                                                                                                                follow up                                                                                                                                                                  
                                                                                    Renal cancer                             6 were ANA positive\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                             2 were anti-CCP positive                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Le Burel 2017 \[[@r4]\]        Nivolumab\                                         Melanoma\                                Out of 908 patients, 30 patients experienced systemic immune-related adverse events: 4 cases of immune cytopenia (including 3 cases of immune thrombocytopenia)\                                                                                                                                                               Yes (in 12 cases)          25 patients (83%) received corticosteroids, and five patients (17%) received immunomodulatory agents (corticosteroid + MTX or iv immunoglobulin)\                          French Registry Retrospective Study
                                 Nivolumab + Ipilimumab\                            Colon and gastric adenocarcinoma\        10 with connective tissue diseases (4 cases of Sjogren syndrome, 3 cases of rheumatoid arthritis, and 3 cases of myositis), 14 with other inflammatory arthritic conditions (including 4 cases of polymyalgia rheumatica, 3 cases of psoriatic arthritis, and 7 cases of seronegative polyarthritis), and 2 with sarcoidosis                              Once the IRAEs had been detected, the symptoms disappeared in 13 patients (43%), decreased in 15 patients (50%), remained stable in 2 patients (7%) and worsened in none   
                                 Pembrolizumab\                                     Renal cell cancer\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                 Atezolimumab\                                      Lung cancer\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                 Durvalumab                                         Cervical and urothelial carcinoma\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                    Brain glioblastoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Pérez-De-Lis 2017 \[[@r37]\]   Ipilimumab (524)\                                  Not declared                             Lupus in 1 patient treated with ipilimumab\                                                                                                                                                                                                                                                                                    Not declared               Not declared                                                                                                                                                               Retrospective study from BIOGEAS Registry
                                 Tremelimumab (2)\                                                                           Vasculitis in 3 patients treated with ipilimumab; 2 patients treated with pembrolizumab.\                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                 Nivolumab (225)\                                                                            Sarcoidosis in 13 patients treated with ipilimumab; 3 patients treated with pembrolizumab; 4 patients treated with nivolumab\                                                                                                                                                                                                                                                                                                                                                                                                        
                                 Pembrolizumab (162)                                                                         Rheumatoid arthritis in 6 patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Suzuki 2017 \[[@r22]\]         Nivolumab\                                         Melanoma\                                Twelve myasthenia gravis cases (0.12%) among 9869 patients with cancer who had been treated with nivolumab, but none among 408 patients treated with ipilimumab                                                                                                                                                                Yes                        Immunosuppressive therapy: High dose corticosteroid therapy, iv immunoglobulin, and plasma exchange                                                                        Retrospective study
                                 Ipilimumab                                         Lung cancer\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                    Colon cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Belkhir 2017 \[[@r11]\]        Nivolumab\                                         Melanoma\                                10 patients developed:\                                                                                                                                                                                                                                                                                                        No (except one case)       Patients with rheumatoid arthritis: 3 treated with DMARDS (with good response) and 3 with steroid or NSAIDS (with resolution of symptoms)\                                 Retrospective study
                                 Pembrolizumab\                                     Endometrial and vagina adenocarcinoma\   Rheumatoid arthritis in 6 cases;\                                                                                                                                                                                                                                                                                                                         Patients with polymyalgia rheumatica were treated with steroid therapy with resolution of symptoms                                                                         
                                 Anti-PDL1                                          Lung adenocarcinoma\                     polymyalgia rheumatica in 4 cases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                    Gastric and colon carcinoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **References**                 **Drugs**                                          **Indications**                          **Clinical Presentation**                                                                                                                                                                                                                                                                                                      **Withdrawal of Drugs**    **Treatment and Outcome**                                                                                                                                                  **Type of Study**

  Calabrese 2017 \[[@r10]\]      Nivolumab+ ipilimumab (7)\                         Melanoma\                                15 patients developed:\                                                                                                                                                                                                                                                                                                        Yes (in 12/15 patients)    Corticosteroid therapy\                                                                                                                                                    Single center retrospective study
                                 Ipilimumab + pembrolizumab (1)\                    NSCLC\                                   sicca syndrome in 5 cases,\                                                                                                                                                                                                                                                                                                                               Infliximab in 2 cases\                                                                                                                                                     
                                 Nivolumab (5)\                                     Renal cell carcinoma                     arthritis in 7 cases,\                                                                                                                                                                                                                                                                                                                                    Etanercept in 2 cases\                                                                                                                                                     
                                 Atezolimumab (1)\                                                                           myositis in 1 case and\                                                                                                                                                                                                                                                                                                                                   Adalimumab in 1 case\                                                                                                                                                      
                                 Durvalumab (1) Tremelimumab (1)                                                             polymyalgia rheumatica in 3 cases.\                                                                                                                                                                                                                                                                                                                       Methotrexate in 2 cases\                                                                                                                                                   
                                                                                                                             Lab tests showed:\                                                                                                                                                                                                                                                                                                                                        These treatments led to significant improvement in 6 patients, moderate improvement in 5 patients and only minimal improvement in 2                                        
                                                                                                                             ANA positivity in 4 cases\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                             FR positivity in 11 cases\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                             Anti-SSA positivity in 1 case\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                             Anti-dsDNA positivity in 1 case                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Cappelli 2017 \[[@r7]\]        Nivolumab + ipilimumab (8)\                        Melanoma\                                13 patients developed:\                                                                                                                                                                                                                                                                                                        Yes                        These therapies were performed:\                                                                                                                                           Retrospective study
                                 Nivolumab or ipilimumab (5)                        NSCLC\                                   Sicca syndrome in 4 cases;\                                                                                                                                                                                                                                                                                                                               Corticosteroid therapy\                                                                                                                                                    
                                                                                    Renal cell carcinoma                     arthritis in 9 cases\                                                                                                                                                                                                                                                                                                                                     Infliximab in 2 cases;\                                                                                                                                                    
                                                                                                                             ANA were positive in 5 out of 13 patients                                                                                                                                                                                                                                                                                                                 Etanercept in 1 case;\                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Adalimumab in 3 cases;\                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       NSAIDS as needed\                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Outcome:\                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       stable disease in 5 cases;\                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       partial response in 6 cases;\                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       progressive disease in 1 case;\                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       non measureable in 1 case                                                                                                                                                  

  Tetzlaff 2018 \[[@r53]\]       Ipilimumab (14) Nivolumab (3) Pembrolizumab (5)\   Melanoma\                                A review of 26 patients (including the 3 from this report) who developed granulomatous/sarcoid-like lesions are described                                                                                                                                                                                                      Yes (in 10/26 patients)    Systemic steroids in 12 patients (44%)\                                                                                                                                    Retrospective study and literature review
                                 Ipilimumab + nivolumab (3)\                        Prostate adenocarcinoma\                                                                                                                                                                                                                                                                                                                                                                           Outcome of sarcoidosis:\                                                                                                                                                   
                                 Anti-PD-L1 (1)                                     NSCLC\                                                                                                                                                                                                                                                                                                                                                                                             Resolution in 14 cases;\                                                                                                                                                   
                                                                                    Hodgkin lymphoma\                                                                                                                                                                                                                                                                                                                                                                                  Improvement in 9 cases;\                                                                                                                                                   
                                                                                    Ovarian cancer\                                                                                                                                                                                                                                                                                                                                                                                    Stable in 1 case;\                                                                                                                                                         
                                                                                    Colorectal carcinoma                                                                                                                                                                                                                                                                                                                                                                               Not reported in 2 cases.\                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Disease response to ICI:\                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Stable in 5 cases;\                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Remission in 10 cases;\                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Progression in 6 cases;\                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Not reported in 5 cases                                                                                                                                                    

  Kostine 2017 \[[@r61]\]        Nivolumab\                                         Melanoma\                                35 (6.6%) out of 524 ICI-treated patients were referred to the Rheumatology Clinic.\                                                                                                                                                                                                                                           No (except one case)       All patients required corticosteroids (max 30 mg/day), leading to clinical improvement or remission. Two patients required DMARDs (MTX).\                                  Single center prospective observational study
                                 Pembrolizumab\                                     Merkel carcinoma\                        Inflammatory arthritis occurred in 20 cases (3.8%), with 7 cases mimicking rheumatoid arthritis, 11 cases PMR, 2 cases psoriatic arthritis                                                                                                                                                                                                                After 6 months, 2 patients were able to discontinue corticosteroids                                                                                                        
                                 Atezolizumab\                                      NSCLC\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                 Avelumab\                                          Renal cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                 Anti-PD1+anti-CTLA4 (5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Lidar 2018 \[[@r5]\]           Nivolumab (4)\                                     Melanoma\                                Polyarthritis in 10 cases\                                                                                                                                                                                                                                                                                                     No (3 cases)\              NSAIDS (11 cases)\                                                                                                                                                         Single center registry
                                 Ipilimumab (1)\                                    Endometrial cancer\                      Oligoarthritis in 1 case\                                                                                                                                                                                                                                                                                                      Withheld (3 cases)\        Steroid therapy (14 cases)\                                                                                                                                                
                                 Ipilimumab + nivolumab (1)\                        Sinonasal cancer\                        Monoarthritis in 1 case\                                                                                                                                                                                                                                                                                                       Off therapy (8 cases)      MTX (8 cases)\                                                                                                                                                             
                                 Pembrolizumab (8)                                  Hodgkin's lymphoma\                      Sarcoidosis in 1 case\                                                                                                                                                                                                                                                                                                                                    Outcomes:\                                                                                                                                                                 
                                                                                    Breast cancer                            Eosinophilic fasciitis in 1 case                                                                                                                                                                                                                                                                                                                          Low disease activity (9 cases)\                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Moderate (1 case)\                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Remission (3 case)\                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Unknown (1 case)                                                                                                                                                           

  **References**                 **Drugs**                                          **Indications**                          **Clinical Presentation**                                                                                                                                                                                                                                                                                                      **Withdrawal of Drugs**    **Treatment and Outcome**                                                                                                                                                  **Type of Study**

  Buder-Bakhaya 2018 \[[@r9]\]   Pembrolizumab or Nivolumab ±Ipilimumab             Melanoma                                 195 patients were included\                                                                                                                                                                                                                                                                                                    Yes, in 7.7% of patients   The majority of patients (73.1%) received NSAIDs with benefit\                                                                                                             Retrospective study
                                                                                                                             26 patients developed arthralgia (mainly large joints).\                                                                                                                                                                                                                                                                                                  5 patients (19.2%) further needed low-dose prednisolone.\                                                                                                                  
                                                                                                                             Of these, 2 were FR ± anti-CCP positive, 10 developed arthritis and 5 progressive osteoarthritis. In 11 patients, arthralgia could not be\                                                                                                                                                                                                                A patient with RA additionally received sulfasalazine and hydroxychloroquine.\                                                                                             
                                                                                                                             specified                                                                                                                                                                                                                                                                                                                                                 Outcomes: 5 patients were able to stop NSAIDs ± low dose prednisolone completely, 6 patients still require NSAIDs ± low dose steroids                                      
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